|
| General Information |
| Business: |
SCYNEXIS is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as a novel oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. SCY-078 has been shown to be effective in vitro and in vivo in animal studies against a broad range of Candida and Aspergillus fungal species, including drug resistant strains. These important pathogens account for approximately 85% of invasive fungal infections in the United States and Europe. SCY-078 was shown to be sufficiently safe and well-tolerated in multiple Phase 1 studies to support progression to Phase 2 studies. We anticipate that the first patient will be enrolled in the second half of 2014 in a Phase 2 study with an oral formulation of SCY-078 for the treatment of invasive Candida infection, a common and often fatal invasive fungal infection, and anticipate beginning studies with an IV formulation of SCY-078 in 2015. |
|
| Industry: |
PHARMACEUTICAL PREPARATIONS |
|
| Employees: |
90 |
Founded: |
1999 |
|
| Contact Information |
| Address: |
3501 C Tricenter Boulevard, Durham, NC 27713, US |
|
|
|
|
|
|
|
| Financial Information |
| |
| Revenues: |
$ 16.9 mil (last 12 months) |
|
| Net Income: |
$ -30.5 mil (last 12 months) |
|
| IPO Profile |
|
|
|
|
